GULLIVER-2 - a single (open-label) and repeat dose (randomised, placebo-controlled) trial to assess the safety, tolerability and pharmacokinetics of GB1211 (Gal-3 inhibitor) in participants with hepatic impairment (Child Pugh B and Child Pugh C)

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 28 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Selvigaltin (Primary)
Indications Liver cirrhosis; Non-small cell lung cancer
Focus Adverse reactions; Pharmacokinetics
Acronyms GULLIVER-2
Sponsors Galecto Inc

Most Recent Events

14 Nov 2023 Results of sub-group analysis comparing the effect of GB1211 vs placebo, presented at The Liver Meeting 2023: 74th Annual Meeting of the American Association for the Study of Liver Diseases.
26 Sep 2023 Status changed from active, no longer recruiting to completed, according to Galecto media release.
10 May 2023 Planned End Date changed from 10 Apr 2023 to 4 Jul 2023.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight